Trials / No Longer Available
No Longer AvailableNCT00719225
A Belatacept Compassionate Use Study for Patients With a Kidney Transplant
Belatacept for Renal Allograft Recipients: A Compassionate Use Program
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
To make belatacept available for recipients of a renal allograft who are currently intolerant to or have contraindications to CNIs and/or m-TOR inhibitors and are either: * unable to construct an adequate immunosuppression regimen due to nonrenal toxicity / contraindication (and withdrawing the causative agent would lead to renal graft loss) OR * at imminent risk of losing the allograft kidney due to nephrotoxicity and have no other options for renal replacement therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Belatacept | IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially |
Timeline
- First posted
- 2008-07-21
- Last updated
- 2021-11-23
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00719225. Inclusion in this directory is not an endorsement.